AVEO AVEO Pharmaceuticals Inc.

7.73
-0.16  -2%
Previous Close 7.89
Open 7.97
Price To Book 17.57
Market Cap 124,303,162
Shares 16,080,616
Volume 473,724
Short Ratio
Av. Daily Volume 719,853
Stock charts supplied by TradingView

NewsSee all news

  1. AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma

    - Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC - AVEO Oncology (NASDAQ:AVEO) today announced that the U.S. Food and Drug Administration

  2. AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2

    AVEO Oncology (NASDAQ:AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective next-generation vascular endothelial growth factor

  3. AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing

    - Final OS Hazard Ratio Improves to 0.97 - - Company to Host Conference Call Today at 8:30 am Eastern Time - AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from the final analysis of overall

  4. AVEO Announces Change to Virtual Annual Meeting of Stockholders

    AVEO Oncology (NASDAQ:AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to

  5. AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update. "Our recent submission of a New Drug Application (NDA) to the U.S. Food and Drug

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2021.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 final data presented at ESMO 2019.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
PDUFA date March 31, 2021.
Tivozanib
Third line treatment of patients with renal cell cancer
Phase 2 trial discontinued due to COVID-19.
Ficlatuzumab and cytarabine
Acute myeloid leukemia (AML)
Phase 1/2 trial has moved to Phase 2 part of trial - May 29, 2020.
FOTIVDA (Tivozanib) and IMFINZI (Durvalumab)
Hepatocellular carcinoma (HCC)
Phase 1b data noted 29% partial response (PR) rate - January 27, 2020.
Ficlatuzumab and nab-paclitaxel
Pancreatic ductal adenocarcinoma (PDAC)

Latest News

  1. AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma

    - Tivozanib assigned PDUFA target action date of March 31, 2021; FDA indicates that it does not currently plan to convene an ODAC - AVEO Oncology (NASDAQ:AVEO) today announced that the U.S. Food and Drug Administration

  2. AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2

    AVEO Oncology (NASDAQ:AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective next-generation vascular endothelial growth factor

  3. AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing

    - Final OS Hazard Ratio Improves to 0.97 - - Company to Host Conference Call Today at 8:30 am Eastern Time - AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from the final analysis of overall

  4. AVEO Announces Change to Virtual Annual Meeting of Stockholders

    AVEO Oncology (NASDAQ:AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to

  5. AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update. "Our recent submission of a New Drug Application (NDA) to the U.S. Food and Drug

  6. AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program

    AVEO Oncology (NASDAQ:AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO's vascular endothelial growth factor receptor tyrosine kinase

  7. AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company's vascular endothelial growth factor receptor

  8. AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

    AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF)

  9. AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update. "The coming months will be an important period for AVEO, with filing of a New Drug

  10. AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split

    AVEO Oncology (NASDAQ:AVEO) today announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective as of 5:00 p.m. Eastern Time today, February 19, 2020. AVEO's common stock will

  11. AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer

    AVEO Oncology (NASDAQ:AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company's vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients

  12. AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

    - Data Presented at the 2020 ASCO GI Cancers Symposium - AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO's

  13. AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer

    AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Erick Lucera as chief financial officer. Mr. Lucera will be responsible for managing all aspects of the Company's financial and accounting functions. "It

  14. AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology. TIVO-3 is the Company's Phase 3 randomized, controlled, multi-center,

  15. AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at

  16. AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

    AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and

  17. AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously Treated With

  18. AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

    AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. "This quarter we have made meaningful progress toward our goal of bringing

  19. AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

    AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF) inhibitory

  20. AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

    - NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – - Company Plans Final OS Analysis in 2Q20 - AVEO Oncology (NASDAQ:AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug

  21. AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

    AVEO Oncology (NASDAQ:AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA® (tivozanib), the Company's once-daily, potent and selective

  22. AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at

  23. Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  24. AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

    - 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - AVEO Oncology